HR Positive | Norton Healthcare

Indication: HR Positive

Phase III post-neoadjuvant study evaluating palbociclib, a Cyclin-Dependent Kinase (CDK)4/6 inhibitor in primary hormone-receptor-positive, HER2 negative breast cancer patients with high relapse risk after standard neoadjuvant treatment – PENELOPE

Sub-indication: Breast Cancer

Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: GBG Forschungs GmbH, Neu-Isenburg

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.